Daniel E. Frigo, Ph.D.

In Memoriam: Bert W. O'Malley, M.D. It is with great sadness that we announce the death of Dr. Bert W. O'Malley, Baylor College of Medicine chancellor, and former chair of the Department of Molecular and Cellular Biology. He also served as the associate director of basic research in the Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine. Considered the ‘founding father’ in the field of molecular endocrinology, Dr. Bert O’Malley was born in Pittsburgh, Pa. and received his Bachelor of Science degree from the University of Pittsburgh and his medical degree from the University of Pittsburgh School of Medicine. He did his clinical internship and residency training at Duke University Medical Center and spent four years at the National Institutes of Health, where he was head of the Molecular Biology Section of the Endocrine Branch of the National Cancer Institute of the National Institutes of Health. He then served as the Lucious Birch Professor and Director of the Reproductive Biology Center at Vanderbilt University before joining Baylor College of Medicine as chair of the Department of Molecular and Cellular Biology in 1973, a position he held for 45 years. During his time in this role, the department was routinely listed in the top five in the nation in securing National Institutes of Health funding; more than five times as No. 1. He published more than 700 papers and holds 29 patents in the fields of gene regulation, molecular endocrinology, steroid receptor and coactive action and cell proteomics and metabolism. In July 2018, O’Malley was named the fourth chancellor of Baylor College of Medicine and stepped down as chair of the department to assume the role of chancellor, but continued to direct his research lab. As chancellor, he advised the president of Baylor College of Medicine, participated in strategic planning activities and acted as an ambassador for the College. He was a member of the NCI-designated Dan L Duncan Comprehensive Cancer Center at Baylor. O’Malley changed the understanding of endocrinology in a fundamental way. He focused his research on the molecular mechanisms that guide gene regulation in endocrinology and endocrine cancers, including how hormones, receptors and coactivators contribute to the disease process. His pioneering work in this field has shown that intracellular hormones and cofactors act at the level of DNA to regulate the production of proteins and affect the function of the cell. Research Highlights: Dr. Bert W. O'Malley received the 2013 Endocrine Regulation Prize of the Foundation IPSEN at the 15th European Congress of Endocrinology on April 29, 2013.. O’Malley’s lab discovered and was the first to solve the structure of a functional receptor-coactivator complex on DNA capable of regulating gene transcription in vitro. In addition, he showed that steroid receptor coactivator-2 (SRC-2), which is highly elevated in a variety of tumors, is likely implicated in metabolic coordination of cancer metastasis, opening the possibility of therapeutically targeting the SRC-2 pathway. His work with steroid receptor coactivator-3 (SRC-3), a prognostic marker for aggressive human breast cancer, showed that small-molecule inhibitors that directly bind SRC-3 cause selective degradation of the complex, hereby killing cancer cells with no observable toxicity. Small-molecule inhibitors represent a new type of oncologic drugs that target coactivators. In addition, Dr. O’Malley’s work showed in a mouse model of heart disease, that stimulating SRC-3 with small-molecule MCB-613 initiated a complex cascade of events in tissue repair and modulation of the inflammatory response that reduced fibrosis, attenuating loss of cardiac function after myocardial infarction. These findings open the possibility of novel therapies to regulate the progression of heart failure via SRC-3. His work also revealed a role for SRC-3 in regulatory immune T cells (Tregs) that promote cancer growth by inhibiting anti-cancer immune responses. He also showed that SRC-3 is significantly enriched in both murine and human Tregs. Inhibiting SRC-3 in Tregs in the lab stopped them from reducing the anti-tumor response, suggesting that modulating SRC-3 in Tregs might help control cancer growth. Dr. O’Malley will be missed greatly and his contributions to cancer research will live on for decades to come.